OBJECTIVES: Evaluate the economic impact of pharmacological management of Alzheimer's Disease, such as acetylcholinesterase and N-methyl-D-aspartate receptor inhibition, by comparing model structures and input parameters.

METHODS: According to PRISMA guidelines, systematic reviews were conducted using Cochrane Library, Embase, and PubMed from 2012-2022 for economic evaluations of pharmacological treatments for ADRD. Inclusion criteria were Population AD or AD-related Dementia, Intervention Pharmaceutical, study design SLR or MA on CEA or CUA, Outcome QALYs or LYs, and criteria score ≥ 5%. Excluded non-English language studies. Extracted data from each study (e.g., authors, sample size, time horizon, journal impact factor, conclusion). Findings are divided into two categories: single treatments and combination treatments.

RESULTS: After screening 411 publications from all databases, 3 SLR studies were included. Thirty-nine studies were screened for full-text, 17 economics studies were eligible for data extraction, and quality checks were performed using Drummond and Phillips checklists. The PRISMA diagram shows the flow of publications through the entire SLR process.

CONCLUSIONS: We recommend Markov models for assessing the cost-effectiveness of future ADRD treatments due to their ability to consider different patient health states.